Skip to content
AnalystLens

IDEXX Laboratories Annual Report, Year Ended Dec 31, 2021

Filing Date
Filed February 16, 2022
Period End
December 31, 2021
Security
IDXX
One revenue dollarkept$0.23
In the record · 2016–202610-K1110-Q338-K98

IDXX filed 11 annual reports (10-K), 33 quarterly reports (10-Q) and 98 current reports (8-K) between 2016 and 2026.

  1. Leadership change8-K · Feb ’21Feb ’21
  2. Leadership change8-K · Mar ’26Mar ’26

Summary

Summary of the 10-K filed February 16, 2022. Cited figures are marked; the original filing is the authoritative source.

IDEXX Laboratories' FY2021 10-K shows a strong year driven by its Companion Animal Group (CAG), which generated 90%a of consolidated revenue.

Total revenue rose 18.8% reported (16.4% organic) to $3.215 billionb, gross margin expanded 80 bps to 58.8%, and operating income grew 34.2% to $932.0 million, or 29.0% of revenue. Diluted EPS was $8.60, up from $6.71. Growth was led by CAG Diagnostics recurring revenue (up 19.9% reported), which reflects rebounding clinical visits, higher diagnostic utilization per visit, and pricing, partly offset by weakness in Livestock, Poultry and Dairy (LPD) from lower African Swine Fever testing demand in China.

Management expects the LPD and OPTI COVID-19 testing revenue to decline in 2022. Cash generation remained solid, with operating cash flow of $755.5 millionc. The company deployed significant capital: $755.5 million in open-market buybacks (about 1.3 million shares), $173.4 million in acquisitions (notably ezyVet and Vet Radar software), and $119.5 million in capex.

Cash fell to $144.5 milliond, and total debt rose to about $924 million including a $73.5 million revolver draw. Gross debt to Adjusted EBITDA was 0.86x and net debt to Adjusted EBITDA was 0.73x, well inside the 3.5x covenant. The company also extended its $1 billion revolving credit facility to December 2026.

Key watch items include a 2022 effective tax rate guided to about 22% (up from 17.5%), an approximately $55 million revenue headwind from a stronger U.S. dollar in 2022, a 2022 capex plan of roughly $180 million, and an ongoing royalty litigation with a $27.5 million accrual against a claim of about $50 million. The company has never paid a cash dividend.

Key Highlights

  1. Revenue reached $3.215 billion, up 18.8% reported and 16.4% organic, led by CAG recurring diagnostics growth.
  2. Operating income rose 34.2% to $932.0 million, with operating margin expanding to 29.0% from 25.7%.
  3. Diluted EPS was $8.60, up from $6.71 in 2020; net income was $744.8 million.
  4. CAG Diagnostics recurring revenue was $2.53 billion (about 79% of consolidated revenue), with IDEXX VetLab consumables up 22.1% and reference lab services up 18.7%.
  5. Returned capital aggressively: $755.5 million of open-market buybacks in 2021, with $4.99 million shares remaining under the authorization, plus $173.4 million spent on acquisitions.
  6. Leverage is conservative, with net debt to Adjusted EBITDA of 0.73x against a 3.5x covenant, while the $1 billion revolver was extended to December 2026.
  7. Headwinds for 2022 include a projected 22% effective tax rate, roughly $55 million of revenue pressure from a stronger dollar, and expected LPD and COVID-19 testing declines.

Follow one dollar

Of each $1.00 of revenue in FY2021, IDEXX Laboratories kept $0.23.

  1. Revenue$3.22B100.0%
  2. Cost of revenue−$1.33B41.2%
  3. Gross profit$1.89B58.8%
  4. Operating costs−$957.4M29.8%
  5. Operating income$932.0M29.0%
  6. Interest, other & tax−$187.2M5.8%
  7. Net income$744.8M23.2%
Computed from 10-KFY2021filed February 16, 2022Computed from this filing’s revenue, gross profit, operating income and net income · right columngrey figure: share of revenue

Where FY2021 revenue went

$3.22B
  • Cost of revenue: $1.33B, 41% of revenue
  • Other operating costs: $796.4M, 25% of revenue
  • Net income: $744.8M, 23% of revenue
  • R&D: $161.0M, 5.0% of revenue
  • Interest, other & tax: $187.2M, 5.8% of revenue

Kept 23% as net income

Full revenue history →

Financial Statements

FY2021 against FY2020

Line itemFY2021FY2020Change
Revenue$3.22B$2.71B+18.8%
Cost of Revenue$1.33B$1.14B+16.8%
Gross Profit$1.89B$1.57B+20.3%
R&D Expenses$161.01M$141.25M+14.0%
Operating Income$932.03M$694.52M+34.2%
Interest Expense$29.81M$33.13M−10.0%
Net Income$744.84M$582.13M+28.0%
EPS (Basic)$8.74$6.82+28.2%
EPS (Diluted)$8.60$6.71+28.2%
Shares Outstanding (Basic)85.20M85.34M−0.2%
Shares Outstanding (Diluted)86.57M86.72M−0.2%

Frequently Asked Questions

  1. What drove IDEXX's strong revenue growth in 2021?

    Growth was driven mainly by CAG Diagnostics recurring revenue, which rose 19.9% reported and 18.1% organically. Strong companion animal demand, rising clinical visits and diagnostic utilization per visit, price increases, and the recovery from 2020 pandemic disruptions all contributed. Instrument placements, software acquisitions, and a rebound in water testing added to the total.

  2. How much cash did IDEXX return to shareholders, and how was it funded?

    IDEXX repurchased about 1.3 million shares for $755.5 million in open-market transactions in 2021, and total repurchases including employee tax withholdings were $771.1 million. Funding came primarily from operating cash flow of $755.5 million, supplemented by a $73.5 million revolver draw. The company has never paid a cash dividend and has no current plans to do so.

  3. What are the main risks or headwinds for 2022?

    Management flagged several headwinds: a projected effective tax rate of about 22% (up from 17.5%), an estimated $55 million revenue reduction and $0.08 EPS hit from a stronger U.S. dollar, continued pressure on LPD revenue from lower African Swine Fever testing in China, and the expected decline in OPTI COVID-19 test revenue. Labor shortages, supply chain constraints, and possible COVID-19 variant impacts on veterinary visits are also cited, as is a royalty lawsuit with a $27.5 million accrual against a claim of about $50 million.

  4. How strong is IDEXX's balance sheet and liquidity?

    Liquidity is solid. Cash was $144.5 million at year-end, with $925.1 million available under the $1 billion revolver. Total debt was about $924 million, and gross debt to Adjusted EBITDA was 0.86x. The company was in compliance with its leverage covenant of 3.5x. Management believes current resources are sufficient for at least the next twelve months.

  5. What is IDEXX's 2022 capital spending and acquisition outlook?

    The company estimated a 2022 capital expenditure plan of about $180 million, including a new warehouse and manufacturing site expansion. In 2021, it spent $119.5 million on capex and $173.4 million on acquisitions, including the ezyVet and Vet Radar cloud software businesses. The filing indicates continued investment in software and reference lab growth, but it does not specify 2022 acquisition plans.